Astellas agrees to pay up to $1.34 billion for rights to Audax cancer treatment

Astellas Pharma agreed to pay as much as $1.34 billion for rights to an experimental cancer treatment from Melbourne-based Audax that has yet to be tested in humans.

Detected & updated continuously · Source: Nebula